Literature DB >> 23649038

Biological properties of melanoma and endothelial cells after plasmid AMEP gene electrotransfer depend on integrin quantity on cells.

Masa Bosnjak1, Lara Prosen, Tanja Dolinsek, Tanja Blagus, Bostjan Markelc, Maja Cemazar, Celine Bouquet, Gregor Sersa.   

Abstract

The data on the biological responsiveness of melanoma and endothelial cells that are targeted by Antiangiogenic MEtargidin Peptide (AMEP) are limited; therefore, the antiproliferative, antimetastatic and antiangiogenic effects of AMEP were investigated in murine melanoma and human endothelial cells after plasmid AMEP gene electrotransfer into the cells in vitro. Plasmid AMEP, a plasmid coding for the disintegrin domain of metargidin targeting specific integrins, had cytotoxic and antiproliferative effects on murine melanoma and human endothelial cells. Among the metastatic properties of cells, migration, invasion and adhesion were investigated. Plasmid AMEP strongly affected the migration of murine melanoma and human endothelial cell lines and also affected the invasion of highly metastatic murine melanoma B16F10 and human endothelial cell lines. There was no effect on cell adhesion on Matrigel(TM) or fibronectin in all cell lines. The antiangiogenic effect was shown with tube formation assay, where human microvascular endothelial cell line (HMEC-1) proved to be more sensitive to plasmid AMEP gene electrotransfer than the human umbilical vein endothelial cell line (HUVEC). The study indicates that antiproliferative and antimetastatic biological responses to gene electrotransfer of plasmid AMEP in murine melanoma cells were dependent on the integrin quantity on melanoma cells and not on the expression level of AMEP. The strong antiangiogenic effect expressed in human endothelial cell lines was only partly dependent on the quantity of integrins and seemed to be plasmid AMEP dose dependent.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23649038     DOI: 10.1007/s00232-013-9550-y

Source DB:  PubMed          Journal:  J Membr Biol        ISSN: 0022-2631            Impact factor:   1.843


  29 in total

Review 1.  Electroporation for drug and gene delivery in the clinic: doctors go electric.

Authors:  Julie Gehl
Journal:  Methods Mol Biol       Date:  2008

2.  Progression-related expression of beta3 integrin in melanomas and nevi.

Authors:  P A Van Belle; R Elenitsas; K Satyamoorthy; J T Wolfe; D Guerry; L Schuchter; T J Van Belle; S Albelda; P Tahin; M Herlyn; D E Elder
Journal:  Hum Pathol       Date:  1999-05       Impact factor: 3.466

3.  Antitumoral and antimetastatic effect of antiangiogenic plasmids in B16 melanoma: Higher efficiency of the recombinant disintegrin domain of ADAM 15.

Authors:  Liévin Daugimont; Gaelle Vandermeulen; Florence Defresne; Caroline Bouzin; Lluis M Mir; Céline Bouquet; Olivier Feron; Véronique Préat
Journal:  Eur J Pharm Biopharm       Date:  2011-02-18       Impact factor: 5.571

Review 4.  Treatment of chronic myeloid leukemia with imatinib mesylate.

Authors:  Ryuzo Ohno
Journal:  Int J Clin Oncol       Date:  2006-06       Impact factor: 3.402

Review 5.  Antitumor effectiveness of electrochemotherapy: a systematic review and meta-analysis.

Authors:  B Mali; T Jarm; M Snoj; G Sersa; D Miklavcic
Journal:  Eur J Surg Oncol       Date:  2012-09-11       Impact factor: 4.424

Review 6.  Integrins in angiogenesis and lymphangiogenesis.

Authors:  Christie J Avraamides; Barbara Garmy-Susini; Judith A Varner
Journal:  Nat Rev Cancer       Date:  2008-05-22       Impact factor: 60.716

7.  Requirement of vascular integrin alpha v beta 3 for angiogenesis.

Authors:  P C Brooks; R A Clark; D A Cheresh
Journal:  Science       Date:  1994-04-22       Impact factor: 47.728

8.  Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma.

Authors:  Adil I Daud; Ronald C DeConti; Stephanie Andrews; Patricia Urbas; Adam I Riker; Vernon K Sondak; Pamela N Munster; Daniel M Sullivan; Kenneth E Ugen; Jane L Messina; Richard Heller
Journal:  J Clin Oncol       Date:  2008-11-24       Impact factor: 44.544

9.  Interaction of metargidin (ADAM-15) with alphavbeta3 and alpha5beta1 integrins on different haemopoietic cells.

Authors:  D Nath; P M Slocombe; P E Stephens; A Warn; G R Hutchinson; K M Yamada; A J Docherty; G Murphy
Journal:  J Cell Sci       Date:  1999-02       Impact factor: 5.285

10.  Direct visualization of electroporation-assisted in vivo gene delivery to tumors using intravital microscopy - spatial and time dependent distribution.

Authors:  Maja Cemazar; Ian Wilson; Gabi U Dachs; Gillian M Tozer; Gregor Sersa
Journal:  BMC Cancer       Date:  2004-11-16       Impact factor: 4.430

View more
  9 in total

1.  Gene electrotransfer of plasmid AMEP, an integrin-targeted therapy, has antitumor and antiangiogenic action in murine B16 melanoma.

Authors:  M Bosnjak; T Dolinsek; M Cemazar; S Kranjc; T Blagus; B Markelc; M Stimac; J Zavrsnik; U Kamensek; L Heller; C Bouquet; B Turk; G Sersa
Journal:  Gene Ther       Date:  2015-04-09       Impact factor: 5.250

2.  Different incubation times of cells after gene electrotransfer in fetal bovine serum affect cell viability, but not transfection efficiency.

Authors:  Masa Bosnjak; Beatriz Canals Lorente; Ziva Pogacar; Vesna Makovsek; Maja Cemazar
Journal:  J Membr Biol       Date:  2014-03-20       Impact factor: 1.843

Review 3.  Novel delivery approaches for cancer therapeutics.

Authors:  Ashim K Mitra; Vibhuti Agrahari; Abhirup Mandal; Kishore Cholkar; Chandramouli Natarajan; Sujay Shah; Mary Joseph; Hoang M Trinh; Ravi Vaishya; Xiaoyan Yang; Yi Hao; Varun Khurana; Dhananjay Pal
Journal:  J Control Release       Date:  2015-10-09       Impact factor: 9.776

4.  Gene Electrotransfer of Plasmid with Tissue Specific Promoter Encoding shRNA against Endoglin Exerts Antitumor Efficacy against Murine TS/A Tumors by Vascular Targeted Effects.

Authors:  Monika Stimac; Tanja Dolinsek; Ursa Lampreht; Maja Cemazar; Gregor Sersa
Journal:  PLoS One       Date:  2015-04-24       Impact factor: 3.240

5.  Gene Electrotransfer of Plasmid-Encoding IL-12 Recruits the M1 Macrophages and Antigen-Presenting Cells Inducing the Eradication of Aggressive B16F10 Murine Melanoma.

Authors:  Ursa Lampreht Tratar; Luisa Loiacono; Maja Cemazar; Urska Kamensek; Vito Michele Fazio; Gregor Sersa; Emanuela Signori
Journal:  Mediators Inflamm       Date:  2017-05-16       Impact factor: 4.711

6.  Clinically Usable Interleukin 12 Plasmid without an Antibiotic Resistance Gene: Functionality and Toxicity Study in Murine Melanoma Model.

Authors:  Urska Kamensek; Natasa Tesic; Gregor Sersa; Maja Cemazar
Journal:  Cancers (Basel)       Date:  2018-02-27       Impact factor: 6.639

7.  Effect of calcium electroporation on tumour vasculature.

Authors:  Barbara Staresinic; Tanja Jesenko; Urska Kamensek; Stine Krog Frandsen; Gregor Sersa; Julie Gehl; Maja Cemazar
Journal:  Sci Rep       Date:  2018-06-20       Impact factor: 4.379

8.  Tumor cell death after electrotransfer of plasmid DNA is associated with cytosolic DNA sensor upregulation.

Authors:  Katarina Znidar; Masa Bosnjak; Nina Semenova; Olga Pakhomova; Loree Heller; Maja Cemazar
Journal:  Oncotarget       Date:  2018-04-10

Review 9.  Tumor angiogenesis and anti-angiogenic gene therapy for cancer.

Authors:  Tinglu Li; Guangbo Kang; Tingyue Wang; He Huang
Journal:  Oncol Lett       Date:  2018-05-17       Impact factor: 2.967

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.